Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024

Rhea-AI Summary

Biomica Ltd. (EVGN) to Participate in JP Morgan 42nd Annual Healthcare Week and Biotech Showcase Conference

REHOVOT, Israel , Dec. 21, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), is gearing up for participation in the JP Morgan 42^nd Annual Healthcare Week, scheduled to run from January 8 to 11, 2024, in San Francisco. Biomica will also be taking part in the Biotech Showcase conference.

Dr. Elran Haber, CEO of Biomica, will be available for one-on-one meetings throughout the week, starting on Monday, January 8, and concluding on Thursday, January 11, 2024. Those interested in scheduling a meeting with Dr. Haber can reach out to Biomica's investor or public relations team."

About Biomica Ltd.:

Biomica is a clinical stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing PRISM system, a proprietary computational platform powered by Evogene's MicroBoost AI tech-engine. licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN).  

For more information, please visit www.biomicamed.com.

About Evogene Ltd.: 

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra. 

For more information, please visit: www.evogene.com. 

Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901

 

View original content:https://www.prnewswire.com/news-releases/biomica-ceo-set-to-attend-jp-morgan-healthcare-week-in-san-francisco-january-8-11-2024-302020942.html

SOURCE Biomica Ltd.

FAQ

What is Biomica Ltd.'s (EVGN) upcoming participation in the JP Morgan 42nd Annual Healthcare Week and Biotech Showcase conference?

Biomica Ltd., a clinical-stage biopharmaceutical company and a subsidiary of Evogene Ltd., will be participating in the JP Morgan 42nd Annual Healthcare Week and Biotech Showcase conference from January 8 to 11, 2024.

Who will be available for one-on-one meetings during the week?

Dr. Elran Haber, CEO of Biomica, will be available for one-on-one meetings throughout the week, starting on Monday, January 8, and concluding on Thursday, January 11, 2024.

How can interested parties schedule a meeting with Dr. Haber?

Interested parties can reach out to Biomica's investor or public relations team to schedule a meeting with Dr. Haber.